ライフサイエンスコーパス: herpes virus

1 ovirus (HCMV) is the prototypical human beta-herpes virus.

2 be an effective strategy for controlling koi herpes virus.

3 ction is the high association with oncogenic herpes viruses.

4 onent of the complex cell-entry machinery of herpes viruses.

5 Static latency is the hallmark of all herpes viruses.

6 rate differences were found against 4 other herpes viruses.

7 the seroconversion rates against four other herpes viruses.

8 of activity that also covers hepatitis B and herpes viruses.

9 n a nuclear egress mechanism akin to that of herpes viruses.

10 ivo human tonsillar tissue system) and human herpes viruses.

11 cute infection in mucosal epithelium, bovine herpes virus 1 (BHV-1) establishes lifelong latency in s

12 We used the bovine herpes virus 1 (BHV-1) latency-related (LR) gene, which

13 Murine herpes virus 1 (HSV-1 KOS) infection triggers T cell-dep

14 sequences of common pathogens, such as human herpes virus 1, can be demonstrated.

15 nsactivator VP16 and its homolog from bovine herpes-virus 1 (BHV-1) can each recruit the human homeod

16 Using the model pathogen Bovine Herpes Virus-1 (BHV-1) this study employs an extended-ga

17 nd is missing in the vFLIP encoded by equine herpes virus 2 that lacks this activity.

18 V and MCMV), Epstein-Barr virus (EBV), human herpes virus 6 (HHV-6), varicella zoster virus (VZV), an

19 Subject 2 had respiratory failure, human herpes virus 6 infection, cytopenias, and no circulating

20 es comprised of genomic lambda-DNA and human herpes virus 6 type B (HHV-6B) DNA, we have used our lab

21 ndidate, such as Epstein-Barr virus or human herpes virus 6.

22 creasing evidence that the neurotropic human herpes viruses 6 and 7 (HHV-6, HHV-7) comprise a signifi

23 nce identity to positional homologs in human herpes viruses 6 and 7.

24 II), varicella-zoster virus (VZV), and human herpes virus-6 (HHV-6) nucleic acid sequences.

25 HSV-2), varicella-zoster virus (VZV), human herpes virus-6, 7, and 8 (HHV-6, HHV-7, and HHV-8), and

26 own CD8 T-cell epitopes from the mouse gamma-herpes virus 68.

27 e as they relate to viral factors-both human herpes virus 8 (HHV-8) and human immunodeficiency virus

28 Human herpes virus 8 (HHV-8) is a geographically limited virus

29 Human herpes virus 8 (HHV-8) or Kaposi sarcoma-associated herp

30 Human herpes virus 8 (HHV-8), also known as Kaposi's sarcoma a

31 Kaposi sarcoma (KS), a human herpes virus 8 (HHV-8; also called KSHV)-induced endothe

32 sarcoma-associated herpes virus (KSHV)/human herpes virus 8 (HHV8) DNA sequences have been demonstrat

33 Infection with human herpes virus 8 (HHV8) has been associated with Kaposi's

34 The human herpes virus 8 (HHV8)-encoded viral FLICE (Fas-associati

35 The human herpes virus 8 (HHV8)-encoded viral FLICE inhibitory pro

36 ed herpesvirus, which is also known as human herpes virus 8 (KSHV/ HHV8), has not been reported in va

37 Human T-cell leukemia virus 1 and human herpes virus 8 genomes are also found in tumor cells in

38 tivity; 14.9% (95% CI: 12.4-17.4%) for human herpes virus 8 infection.

39 sarcoma (KS)-associated herpesvirus or human herpes virus 8 is considered the etiological agent of KS

40 sarcoma-associated herpes virus (KSHV)/human herpes virus 8 is oncogenic and stimulates angiogenesis

41 The KS-associated herpesvirus/human herpes virus 8 open reading frame 74 encodes a constitut

42 Kaposi sarcoma-associated herpesvirus/human herpes virus 8 replication and uptake of the ORF45 tegum

43 e at increased risk for development of human herpes virus 8(HHV-8)-associated Kaposi's sarcoma (KS).

44 remains uncertain, a new herpes virus, human herpes virus 8, has been identified in the rare subset o

45 Kaposi sarcoma-associated herpesvirus/human herpes virus 8.

46 chemokine homologue that is encoded by human herpes virus 8.

47 Human herpes virus-8 (HHV-8) drives the hypercytokinemia in al

48 hese interactions were disrupted by an human herpes virus-8 (HHV-8)-coded oncoprotein, vIRF1, and con

49 Human herpes virus-8 and angiogenesis, both involved in the pa

50 happen following reciprocal actions of human herpes virus-8 infection, immunosuppression, and chemica

51 Herpes viruses account for 7% of all scleritis cases and

52 ch would otherwise be resistant to oncolytic herpes virus alone.

53 which are infected with KSHV (Kaposi sarcoma herpes virus, also named HHV-8).

54 e synaptic vesicle, we have used a defective herpes virus amplicon expression system to study the tar

55 Thus, we have tested whether herpes virus amplicon vectors expressing CAT or GPX stil

56 Prophylaxis for herpes virus and Pneumocystis carinii is standard with t

57 Retention of human herpes virus and tumor-associated antigen (TAA)-specific

58 ocess, conserved among dsDNA viruses such as herpes viruses and bacteriophages, is key to forming inf

59 for serologic studies of IgE and IgG to four herpes viruses and constitutive specimens for genotyping

60 unds 2 and 5-9, but 4 was active against two herpes viruses and cytotoxic in the micromolar range.

61 gation for treatment of infections caused by herpes viruses and orthopoxviruses.

62 mune responses to clinically important human herpes viruses and to the TAA WT1.

63 cancer), viral (e.g., human papillomavirus, herpes virus) and bacterial (e.g., Helicobacter pylori,

64 among the bZIPs and among proteins from five herpes viruses, and determining relative protein duplica

65 among the members of the alpha subfamily of herpes viruses, and the US9 gene product lacks lysines.

66 sue, Allan et al. conclude that transport of herpes-virus antigens to lymph nodes by dendritic cells

67 gesia and demonstrate the use of recombinant herpes viruses as tools for studying gene function in sp

68 phosphorylation and its deubiquitination by Herpes virus associated ubiquitin-specific protease (Hau

69 stein-Barr virus (EBV) is an oncogenic gamma-herpes virus associated with malignancies that develop i

70 bacteria (mostly mycobacteria) and viruses (herpes viruses at least), due principally to the impairm

71 A recombinant herpes virus carrying human preproENK cDNA was used to m

72 eption, a recombinant, replication-defective herpes virus carrying the human preproenkephalin cDNA wa

73 Human CMV (HCMV), a highly prevalent herpes virus causing lifelong, usually latent, infection

74 G207 is an oncolytic herpes virus deficient in RR, a rate-limiting enzyme for

75 anscription PCR were performed to screen for herpes virus DNA.

76 We found that herpes viruses (e.g., subtypes HHV4, HHV5, and HHV6) tha

77 ily member LIGHT and the TNF family receptor herpes virus entry mediator (HVEM) co-stimulates T cells

78 an HEp-2 cells or porcine cells that express herpes virus entry mediator (HVEM) for virus and recepto

79 Deficiency of either BTLA or its ligand herpes virus entry mediator (HVEM) resulted in reduced n

80 ber expressed by activated T cells, binds to herpes virus entry mediator (HVEM) which is constitutive

81 abnormal in 40% of FL patients, encodes the herpes virus entry mediator (HVEM) which limits T-cell a

82 The herpes virus entry mediator (HVEM), a member of the tumo

83 cells and dependent on the LIGHT receptors, herpes virus entry mediator (HVEM), and lymphotoxin-beta

84 In addition, BTLA's ligand, herpes virus entry mediator (HVEM), was found constituti

85 cifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (Fa

86 ng respiratory virus infection, we show that herpes virus entry mediator (HVEM; TNFRSF14), a member o

87 y, we demonstrate that a cellular ligand for herpes virus entry mediator and lymphotoxin receptor (LI

88 y reported that LIGHT (a cellular ligand for herpes virus entry mediator and lymphotoxin receptor), a

89 Inhibition of LIGHT (a cellular ligand for herpes virus entry mediator and lymphotoxin receptor)/he

90 entry mediator, blocks the immunoinhibitory herpes virus entry mediator B and T lymphocyte attenuato

91 ymphotoxin beta receptor-deficient mice, and herpes virus entry mediator on donor T cells is required

92 that competes for glycoprotein D binding to herpes virus entry mediator on T cells (TNFSF14)) activa

93 locks immunoinhibitory signaling through the herpes virus entry mediator pathway.

94 sis factor receptor superfamily member HVEM (herpes virus entry mediator).

95 with herpes simplex virus glycoprotein D for herpes virus entry mediator, a receptor expressed by T l

96 n, and competing with HSV glycoprotein D for herpes virus entry mediator, a receptor expressed by T l

97 n, and competing with HSV glycoprotein D for herpes virus entry mediator, a receptor expressed by T l

98 ing receptors, lymphotoxin beta receptor and herpes virus entry mediator, because LIGHT Tg mesenteric

99 glycoprotein D, which through binding to the herpes virus entry mediator, blocks the immunoinhibitory

100 lymphotoxin-beta receptor (LTbetaR) but not herpes virus entry mediator.

101 rotein that competes with glycoprotein D for herpes virus entry on T cells) is a tumor necrosis facto

102 Lytic replication of the human gamma herpes virus Epstein-Barr virus (EBV) is an essential pr

103 Members of the herpes virus family and hepatitis B virus (HBV) have bee

104 f viruses, especially those belonging to the herpes virus family and most importantly in varicella zo

105 uman cytomegalovirus (HCMV), a member of the herpes virus family, may play a role in the development

106 The Kaposi's sarcoma-associated herpes virus gene product K3 (KK3) subverts the MHC clas

107 A recognizes the same surface on HVEM as gD (herpes virus glycoprotein D) and utilizes a similar bind

108 I IEk, the nonclassical MHC T10/T22, and the Herpes virus glycoprotein gI-indicates that gamma delta

109 V-8, also called Kaposi's sarcoma-associated herpes virus) has been linked to Kaposi's sarcoma and pr

110 Many enveloped viruses, including herpes viruses, hepatitis B virus (HBV), and hepatitis C

111 the glycolytic activation induced by another herpes virus, herpes simplex virus type 1 (HSV-1).

112 ein and kinesin-1 with adenovirus, the alpha herpes viruses: herpes simplex virus (HSV1) and pseudora

113 Sequential human herpes virus (HHV) reactivation is well known in drug re

114 a-associated lymphoid tissue lymphoma, human herpes virus (HHV)-6, HHV-7, chlamydia, Epstein-Barr vir

115 ned possible pathogen(s) for detecting human herpes virus (HHV1-HHV7), HEV, or Mycoplasma pneumoniae

116 Epstein-Barr virus remains uncertain, a new herpes virus, human herpes virus 8, has been identified

117 carcinoma in other organs or any history of herpes virus, human papilloma virus, or human immunodefi

118 In addition to adeno- and herpes viruses, human papillomavirus (HPV) can serve as

119 Cells expressing herpes virus ICP-47 block the generation of this epitope

120 tify BAG3, a co-chaperone, as a regulator of herpes virus immediate early gene expression.

121 The Kaposi's sarcoma-associated herpes virus immediate-early lytic cycle trigger protein

122 dynamically regulated upon infection with a herpes virus in a manner that impacts virus replication.

123 ascular endothelial cells with KS-associated herpes virus in vitro results in a lymphatic reprogrammi

124 hat is used in the treatment of a variety of herpes viruses in immunocompromised patients and in a ge

125 ty-five (74.4%) of these were diagnosed with herpes virus infection, 5 (10.6%) with tuberculosis, and

126 th scleritis, 35 of whom were diagnosed with herpes virus infection, seen at 2 tertiary referral cent

127 eaths from disseminated histoplasmosis and a herpes virus infection.

128 fter treatment of preexisting drug-resistant herpes virus infection.

129 virus 8 (HHV-8) or Kaposi sarcoma-associated herpes virus is the etiologic agent of Kaposi sarcoma, p

130 Epstein-Barr virus (EBV), a human herpes virus, is associated with a variety of malignanci

131 Varicella-zoster virus (VZV), an alpha-herpes virus, is the causative agent of chickenpox, shin

132 osely associated with the lymphotropic gamma herpes virus Kaposi's sarcoma-associated herpes virus (K

133 evidence suggests an association with a new herpes virus, Kaposi's sarcoma-associated herpes virus (

134 Koi herpes virus (KHV), a highly virulent disease affecting

135 quantitation of Kaposi's sarcoma-associated herpes virus (KSHV or human herpesvirus 8) DNA was evalu

136 tein-Barr virus or Kaposi sarcoma-associated herpes virus (KSHV) are exquisitely sensitive to this co

137 Kaposi sarcoma-associated herpes virus (KSHV) contains a gene that has functional

138 Kaposi's sarcoma-associated herpes virus (KSHV) contributes to the pathogenesis of K

139 Kaposi sarcoma-associated herpes virus (KSHV) encodes a D-like cyclin (K-cyclin) t

140 The Kaposi's Sarcoma associated Herpes virus (KSHV) encodes two genes with the potential

141 Virus (EBV), and Kaposi's Sarcoma-associated Herpes Virus (KSHV) in a fingerprick volume (50 microL)

142 Kaposi's sarcoma-associated herpes virus (KSHV) infects B cells and microvascular en

143 Kaposi's sarcoma-associated herpes virus (KSHV) is a recently identified human gamma

144 Kaposi's sarcoma-associated herpes virus (KSHV) is implicated in the pathogenesis of

145 Kaposi's sarcoma-associated herpes virus (KSHV) is the causative agent of PEL.

146 Kaposi's sarcoma-associated herpes virus (KSHV) polyadenylated nuclear (PAN) RNA fac

147 miRNA encoded by Kaposi's-sarcoma-associated herpes virus (KSHV) shows significant homology to cellul

148 mma herpes virus Kaposi's sarcoma-associated herpes virus (KSHV), also called human herpesvirus 8.

149 d by the oncogenic Kaposi sarcoma-associated herpes virus (KSHV), constitutively activates the canoni

150 ransformation mediated by the Kaposi sarcoma herpes virus (KSHV)-encoded G-protein-coupled receptor (

151 associated with Kaposi's sarcoma-associated herpes virus (KSHV).

152 ith infection by Kaposi's sarcoma-associated herpes virus (KSHV).

153 Kaposi's sarcoma-associated herpes virus (KSHV)/human herpes virus 8 (HHV8) DNA sequ

154 ) encoded by the Kaposi's sarcoma-associated herpes virus (KSHV)/human herpes virus 8 is oncogenic an

155 y discovered the Kaposi's sarcoma-associated herpes virus (KSHV/HHV-8) in an uncommon and unusual sub

156 ew herpes virus, Kaposi's sarcoma-associated herpes virus (KSHV/HHV-8), and primary effusion lymphoma

157 roliferation that requires infection with KS herpes virus (KSHV/HHV-8).

158 atently infected Kaposi's sarcoma-associated herpes-virus (KSHV)-associated tumor cells have both end

159 s ks-vFLIP (produced by the Kaposi's sarcoma herpes virus [KSHV]), which associates with IKKgamma, an

160 G207 is an oncolytic herpes virus lacking UL39, the gene encoding RR.

161 ptors and the associated signal molecules in herpes virus latency and uncover a novel paradigm that s

162 The restriction of herpes virus latency to mammalian sensory ganglia has le

163 liferation response to HIV and opportunistic herpes viruses may lead to resistance to central nervous

164 , which likely do not replicate, and certain herpes viruses, may also play a role in disease pathogen

165 sease (MD), caused by the oncogenic MD avian herpes virus (MDV), is a major source of economic losses

166 T-cell repertoires supports the notion that herpes virus-mediated continuously de novo priming of ne

167 ved control of infection with a recombinant -herpes virus, MHV-68, engineered to express SIINFEKL pep

168 c infections such as HIV, hepatitis C virus, herpes viruses, mycobacteria, and fungal and parasitic i

169 erine protease from cytomegalovirus (CMV), a herpes virus of the beta subfamily.

170 cases cannot be attributed to infection with herpes viruses or HBV.

171 , infection of macrophages lacking TRAM with herpes viruses or the bacterium Staphylococcus aureus le

172 hymidine kinase (HSV-1 TK) is the major anti-herpes virus pharmacological target, and it is being uti

173 (the ENE of the Kaposi's sarcoma-associated herpes virus polyadenylated nuclear RNA) are not efficie

174 ty, viral infections (cytomegalovirus, other herpes viruses) predominate and may coexist with bacteri

175 MV protease, offering a structural basis for herpes virus protease ligand specificity.

176 further evidence to support the finding that herpes virus proteases have a fold and active site disti

177 Recent evidence that a herpes virus protein lacking a classical secretory signa

178 sion in intestinal epithelial cells of M3, a herpes virus protein that binds and inhibits multiple ch

179 The activation domain from the herpes virus protein VP16 restored the ability of the ba

180 The alpha-herpes virus (pseudorabies, PRV) was used to observe cen

181 Daily suppression of this herpes virus reduces plasma HIV-1 concentrations, but wh

182 Most tailed bacteriophages and herpes viruses replicate genome as a concatemer which is

183 Most recently, I have been studying herpes virus replication and inadvertently wandered into

184 se inhibitors, and its inhibitory effects on herpes virus replication are compelling reasons to pursu

185 A better understanding of herpes virus replication will help the development of ne

186 aging reactions of tailed bacteriophages and herpes viruses require the activity of a terminase enzym

187 rtance of the B locus in the response to the herpes virus responsible for Marek's diseases.

188 Furthermore, infection with the KS herpes virus results in up-regulation of VEGF and trigge

189 tion of these compounds for activity against herpes viruses revealed that the new compounds were less

190 ins, and shells of tailed bacteriophages and herpes viruses show conserved features.

191 Oncolytic herpes viruses show promise for cancer treatment.

192 Both cases were negative for EBV, herpes virus simplex, and cytomegalovirus (CMV).

193 rpes simplex virus type 1 (HSV-1), and human herpes virus six (HHV-6) and for cytotoxicity.

194 ment strategies against infections caused by herpes viruses such as cytomegalovirus, Epstein-Barr vir

195 ansplantation may extend beyond CMV to other herpes viruses, such as varicella zoster virus and possi

196 neurons following CAmy or PLH injection of a herpes virus that expresses red fluorescent protein foll

197 Epstein-Barr virus (EBV) is a human herpes virus that infects >90% of individuals.

198 Epstein-Barr virus (EBV), a ubiquitous herpes virus that infects 90% of humans by adulthood, is

199 Epstein-Barr virus (EBV) is a herpes virus that is associated with several human cance

200 galovirus (HCMV) is a clinically significant herpes virus that maintains a lifelong infection in the

201 Cytomegalovirus (CMV) is a ubiquitous herpes virus that persists in the host in a latent state

202 erpesvirus 6 (HHV-6), a newly described beta-herpes virus that shares homology with cytomegalovirus (

203 daloid pathway, was performed using an alpha-herpes virus, the Bartha strain of pseudorabies virus (P

204 ed with neurological disease caused by other herpes viruses, the clinical features of acute EBV myelo

205 for viruses as dissimilar as lambda and the herpes viruses, the model may find general utility in ou

206 In tailed bacteriophages and herpes viruses, the viral DNA is packaged through the po

207 (HCV), human papillomavirus (HPV), and human herpes viruses, this paradigm is not applicable.

208 The herpes virus thymidine kinase (HSV-tk) is a critical enz

209 In contrast, herpes virus thymidine kinase (HSV1-TK) readily activate

210 thetic Renilla luciferase (hRluc), EGFP, and Herpes virus thymidine kinase (sr39TK).

211 ing element and a kappaB motif linked to the herpes virus thymidine kinase promoter were able to medi

212 expression in the context of a heterologous (herpes virus thymidine kinase) promoter.

213 In addition, herpes virus thymidine kinases are being explored in gen

214 IITA is very similar to that mediated by the herpes virus transactivator VP16 in the ways that have b

215 ein interactions, including that between the herpes virus transcriptional activator VP16 and the mamm

216 Important examples include HIV, herpes viruses, tuberculosis, leprosy, and malaria.

217 ssion of the ICP0-related proteins of bovine herpes virus type 1 (BHV-1), equine herpesvirus type 1 (

218 Herpes virus type 1 thymidine kinase (HSV1-tk) and the m

219 eutic efficacy for hepatic CRC tumors, using herpes virus type 1 thymidine kinase (HSV1-tk) as a ther

220 uthors examined whether maternal exposure to herpes virus type 2 is associated with risk for adult sc

221 omatitis virus, bluetongue virus, and bovine herpes virus type 2.

222 ied to a clinically relevant real-time human herpes virus type 6 (HHV6) PCR assay that used a minor g

223 ia/lymphoma virus type 2 (HTLV-2), and human herpes virus type 8 (HHV-8) genomes.

224 pha (IFN-alpha) to induce apoptosis in Human Herpes Virus Type 8 (HHV-8) positive Primary Effusion Ly

225 Infection with human herpes virus type 8 (HHV8), a B cell lymphotrophic virus

226 nfections such as Helicobacter pylori, human herpes virus type 8 and cytomegalovirus.

227 f noninvasive imaging of adenoviral-mediated herpes virus type one thymidine kinase (HSV1-tk) gene tr

228 he feasibility and sensitivity of imaging of herpes virus type one thymidine kinase (HSV1-tk) gene tr

229 The viruses are bovine herpes virus types 1, 3, 4 and 5, bovine viral diarrhea

230 iquitin (Ub) ligase domains, one, designated herpes virus Ub ligase 1 (HUL-1) located in a domain enc

231 domain encoded in exon 3 and one designated herpes virus Ub ligase 2 (HUL-2) associated with the rea

232 Tailed bacteriophages and herpes viruses use powerful ATP-driven molecular motors

233 Tailed bacteriophages and herpes viruses use powerful molecular machines to packag

234 Tailed bacteriophages and herpes viruses use powerful molecular motors to transloc

235 as well as imaging of gene delivery using a herpes virus vector.

236 d rat hippocampal neurons, using a defective herpes virus vector.

237 ignment scores for PPI networks of different herpes viruses, we reconstruct their phylogenetic relati

238 The interactions of herpes virus with vessels wall remind us of the affinity

239 lation has often centered on the neurotropic herpes viruses, with herpes simplex virus 1 (HSV1) consi

240 The equine herpes virus zinc ring domain nuclear magnetic resonance

241 sses 54% sequence similarity with the equine herpes virus zinc ring domain.